Pharmacokinetic Variability of Daptomycin during Prolonged Therapy for Bone and Joint Infections-Reference-Cited by-同舟云学术

Pharmacokinetic Variability of Daptomycin during Prolonged Therapy for Bone and Joint Infections

Published:2016-05 Issue:5 Volume:60 Page:3148-3151
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Goutelle Sylvain¹²³,Roux Sandrine⁴,Gagnieu Marie-Claude⁵,Valour Florent⁴,Lustig Sébastien⁶,Ader Florence⁴⁶⁷,Laurent Frédéric²⁶⁷,Chidiac Christian⁴⁶⁷,Ferry Tristan⁴⁶⁷

Affiliation:

1. Hospices Civils de Lyon, Groupement Hospitalier de Gériatrie, Service Pharmaceutique, Lyon, France

2. ISPB, Faculté de Pharmacie de Lyon, Université Lyon 1, Lyon, France

3. UMR CNRS 5558, Laboratoire de Biométrie et Biologie Evolutive, Université Lyon 1, Villeurbanne, France

4. Department of Infectious Diseases, Hospices Civils de Lyon, Lyon, France

5. Hospices Civils de Lyon, Groupement Hospitalier Edouard Herriot, Laboratoire de Biochimie et Biologie Moléculaire, UF de Pharmacologie Spécialisée, Lyon, France

6. Claude Bernard Lyon 1 University, Lyon, France

7. International Centre for Research in Infectiology, CIRI, INSERM U1111, CNRS UMR5308, ENS de Lyon, UCBL1, Lyon, France

Abstract

ABSTRACT The interindividual and intraindividual variabilities in daptomycin pharmacokinetics were investigated in 23 patients (69 pharmacokinetic profiles) who were treated for several months for bone and joint infections. Population daptomycin clearance was significantly influenced by renal function and was significantly higher in male than in female patients. We observed significant intraindividual changes in daptomycin clearance, which were uncorrelated with changes in renal function, suggesting that therapeutic drug monitoring is important in patients receiving prolonged daptomycin therapy.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02597-15

Reference13 articles.

1. Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society of Americaa

2. Population Pharmacokinetics of Daptomycin

3. Daptomycin Pharmacokinetics and Pharmacodynamics in a Pooled Sample of Patients Receiving Thrice-Weekly Hemodialysis

4. Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections

5. Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revolutionizing Daptomycin Dosing: A Single 7–11-Hour Sample for Pragmatic Application;Clinical Infectious Diseases;2024-03-29

2. Comparison of daptomycin and glycopeptide efficacy and safety for the treatment of Gram-positive infections: a systematic review and meta-analysis;Journal of Antimicrobial Chemotherapy;2024-02-07

3. Daptomycin Exposure as a Risk Factor for Daptomycin-Induced Eosinophilic Pneumonia and Muscular Toxicity;Clinical Infectious Diseases;2023-07-19

4. Bayesian prediction-based individualized dosing of anti-methicillin-resistant Staphylococcus aureus treatment: Recent advancements and prospects in therapeutic drug monitoring;Pharmacology & Therapeutics;2023-06

5. Daptomycin Physiology-Based Pharmacokinetic Modeling to Predict Drug Exposure and Pharmacodynamics in Skin and Bone Tissues;Clinical Pharmacokinetics;2022-08-16